Clinical pharmacokinetics of ropinirole

Clinical Pharmacokinetics

Volumn 39, Issue 4, 2000, Pages 243-254

  Kaye, Clive M ^a   Nicholls, Briony ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b The Frythe ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIGOXIN; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ESTROGEN; IBUPROFEN; ROPINIROLE; SELEGILINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

COMORBIDITY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG INACTIVATION; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HORMONE SUBSTITUTION; HUMAN; KIDNEY DISEASE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0033765997     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039040-00001     Document Type: Review

References (65)

1. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998; 13: 46-51
2. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease [published erratum: Neurology 1999; 53: 1162]. Neurology 1999; 53: 364-70
3. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study [056 Study Group], Mov Disord 1998; 13: 39-45
4. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91
5. Rascol O, 056 Study Group. Motor complications in a 5-year comparative trial of the dopamine agonist ropinirole and Ldopa [abstract]. Mov Disord 2000; 15 Suppl. 3: 121: P634
6. Dechant KL, Plosker GL. Ropinirole. CNS Drugs 1997; 8: 335-41
7. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 1998; 21: 169-75
8. Montastruc JL, Rascol O, Senard J-M. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999; 14: 725-30
9. Phillips P. Several classes of new drugs emerging for Parkinson disease. JAMA 1999; 282: 929-31
10. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51: 1057-62
11. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 1999; 106: 925-9
12. 2 receptormediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838: 51-9
13. 2 receptor mediated antioxidant and neuroprotective effects of ropinirole [abstract]. Parkinsonism Relat Disord 1999; 5 Suppl.: S81(P-TU-123)
14. Galvez-Jimenez N, Khan T. Ropinirole and restless legs syndrome. Mov Disord 1999; 14: 890-2
15. Ondo W. Ropinirole for restless leg syndrome. Mov Disord 1999; 14: 138-40
16. Gottwald MD, Bainbridge JL, Dowling GA, et al. New pharmacotherapy for Parkinson's disease. Ann Pharmacother 1997; 31: 1205-17
17. Malmberg C. New therapies for Parkinson's. Pharm Pract 1998; 14: 42-50
18. Miyasaki JM. Ropinirole: a clinical profile. Todays Ther Trends 1998; 16: 177-92
19. Ropinirole hydrochloride. In: Dollery C, editor. Therapeutic drugs. Vol. 2. 2nd ed. Edinburgh: Churchill Livingstone, 1999: R50-4
20. Factor SA. Dopamine agonists. Med Clin North Am 1999; 83: 415-43
21. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm 1999; 56: 217-24
22. Zesiewicz TA, Hauser RA. Ropinirole in the treatment of Parkinson's disease. Expert Opin Invest Drugs 1999; 8: 697-710
23. 2 agonist. Pharmacol Biochem Behav 1991; 38: 147-54
24. 2, D3 and D4 receptors expressed in Chinese Hamster Ovary Cells. Br J Pharmacol 1999; 127: 1696-702
25. 3 receptors: relevance for drug treatment of Parkinson's disease. CNS Drugs 1999; 12: 391-402
26. 3 affinity of the novel dopaminergic agonist ropinirole [abstract]. New Trends Clin Neuropharmacol 1994; 8: 298
27. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995; 45 Suppl. 3: S6-12
28. Pearce RKB, Banerji T, Jenner P, et al. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug naïve MPTP-treated common marmosets [abstract]. Br J Pharmacol 1996; 118 Suppl.: 37P
29. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45 Suppl.: 231-8
30. Stocchi F, Destée A. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism Relat Disord 1998; 4: 183-8
31. 2-receptor agonist. Br J Clin Pharmacol 1989; 28: 435-41
32. 2-dopaminergic agonist on supine resting and stimulated circulatory and neuro-endocrine variables in healthy volunteers. Arzneimittelforschung 1990; 40: 7-12
33. Swagzdis JE, Mico B A. Liquid Chromatographic determination of 4(2-di-N,N-propylaminoethyl)-2-(3H)-indolone in rat, dog, and human plasma with ultraviolet detection. J Pharm Sci 1986; 75: 90-1
34. 2-receptor agonist. Br J Clin Pharmacol 1991; 32: 483-8
35. Ramji JV, Keogh JP, Blake TJ, et al. Disposition of ropinirole in animals and man. Xenobiotica 1999; 29: 311-25
36. Boothman BR, Spokes EGS. Pharmacokinetic data for ropinirole [letter]. Lancet 1990; 336: 814
37. Beerahee A, Nichols AI, Aluri J, et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Br J Clin Pharmacol 1997; 43: 556P-7P
38. Swagzdis JE, Wittendorf RW, DeMarinis RM, et al. Pharmacokinetics of dopamine-2 agonists in rats and dogs. J Pharm Sci 1986; 75: 925-8
39. Jenner P, Tulloch I. The preclinical pharmacology of ropinirolereceptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow CW, Obeso JA, editors. Beyond the decade of the brain. Dopamine agonists in early Parkinson's disease. Vol. 2. Royal Tunbridge Wells: Wells Medical, 1997: 115-28
40. Wittendorf R, Mico B. Plasma protein binding and blood-toplasma partition ratio of SKNF 101468 and SKNF 89124 in rat, dog and human blood. Report number BP004BA. Harlow (UK): SmithKline Beecham Pharmaceuticals, 1986. (Data on file)
41. 3H-SKNF 101468 in monkey and human blood. Report number BP-1001. Harlow (UK): SmithKline Beecham Pharmaceuticals, 1992. (Data on file)
42. Ramji J, Keogh J, Taylor A, et al. Pharmacokinetics of ropinirole hydrochloride: absorption, distribution, metabolism and excretion of ropinirole hydrochloride after single and repeat administration to rats and monkeys. Jpn Pharmacol Ther 1996; 24 Suppl. 11: 47-60 (S-1765-S-1778)
43. Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 1997; 25: 840-4
44. Beerahee A, Nichols A, Aluri J, et al. Population pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of ropinirole in parkinsonian patients. Report number BF1019. Harlow (UK): SmithKline Beecham Pharmaceuticals, 1995. (Data on file)
45. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36: 425-38
46. Hubble J, Koller WC, Atchison P, et al. Linear pharmacokinetic behaviour of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 2000; 40: 641-6
47. Urae A, Inokawa Y, Nishioka Y. Phase I clinical investigation of ropinirole hydrochloride (paper 3): pharmacokinetics after single and repeat oral administration to Japanese volunteers. Jpn Pharmacol Ther 1996; 24 Suppl. 11: 87-97 (S1085-S-1815)
48. Miyashita N, Narabayashi H, Furukazu H, et al. Pharmacokinetic study of ropinirole hydrochloride (SK&F 101468) in patients with Parkinson's disease. Jpn Pharmacol Ther 1996; 24 Suppl. 11: 291-303 (S-2009-S-2021)
49. Taylor AC, Beerahee A, Citerone DR, et al. Linear pharmacokinetics of ropinirole in patients with Parkinson's disease. Br J Clin Pharmacol 1998; 45: 204P
50. Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998; 45: 412-5
51. Massoud N. Pharmacokinetic considerations in geriatric patients. In: Benet LZ, Massoud N, Gambertoglio JG, editors. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984: 283-310
52. Beerahee A, Nichols AI, Aluri J, et al. Population pharmacokinetics of ropinirole in parkinsonian patients. Int Pharm Abstr 1996; 33: 21
53. Tornatore KM, Kanarkowski R, McCarthy TL, et al. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol 1982; 23: 129-34
54. Dalvi A, Ford B. Antiparkinsonian agents: clinically significant drug interactions and adverse effects, and their management. CNS Drugs 1998; 9: 291-310
55. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-4
56. Bloomer JC, Clarke SE, Chenery RJ. An assessment of the potential of ropinirole, a dopamine receptor agonist, to inhibit various human cytochrome P450 enzymes [abstract]. Br J Pharmacol 1998; 124:41P
57. Bloomer JC, Taylor MA, Clarke SE, et al. An assessment of the potential of ropinirole and its N-despropyl and hydroxy metabolites to inhibit various human cytochrome P450 enzymes. Neurology 1999; 52 Suppl. 2: A410-11 (P05.039)
58. Taylor AC, Beerahee A, Citerone D, et al. Lack of a pharmacokinetic interaction at steady state between ropinirole and Ldopa in patients with Parkinson's disease. Pharmacotherapy 1999; 19: 150-6
59. Taylor AC, Beerahee A, Citerone D, et al. The effect of steadystate ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Br J Clin Pharmacol 1999; 47: 219-22
60. Dobbs RJ, O'Neill CJA, Deshmukh AA, el al. Serum concentration monitoring of cardiac glycosides. Clin Pharmacokinet 1991; 20: 175-93
61. Wrighton SA, Vanden Branden M, Ring BJ. The human drug metabolising cytochromes P450. J Pharmacokinet Biopharm 1996; 24: 461-73
62. Thalamas C, Taylor A, Brefel-Courbon C, et al. Lack of phar-macokinetic interaction between ropinirole and theophylline in patients With Parkinson's disease. Eur J Clin Pharmacol 1999; 55: 299-303
63. Cooper SM, Eagle S, Jones BA, et al. A study to investigate the effect of repeat oral doses of ciprofloxacin on steady-state ropinirole pharmacokinetics in parkinsonian patients. Report number 1018468/102. Harlow (UK): SmithKline Beecham Pharmaceutical, 1998. (Data on file)
64. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-9
65. Korczyn AD, Rascol O, Adler CH, et al. Dosing with ropinirole in a clinical setting [abstract]. Parkinsonism Relat Disord 1999; 5 Suppl.: S77 (P-TU-105)